Source:http://linkedlifedata.com/resource/pubmed/id/10070909
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1999-3-11
|
pubmed:abstractText |
In 24 diabetic patients with advanced renal failure (creatinine clearance [C(Cr)] < 35 mL/min), we prospectively studied serum tumor necrosis factor-alpha (TNF-alpha) levels, the possible relationship with urinary protein excretion, and the effects of pentoxifylline (PTF) administration. PTF (400 mg daily) was administered for 6 months to 14 patients, and the results were compared with data from a control group (n = 10). Baseline parameters were similar in both groups. At the end of the study, urinary protein excretion and serum TNF-alpha decreased in the active group from 2.7 (1.2 to 5.8) g/d and 569 +/- 285 pg/mL to 1.1 (0.3 to 4.0) g/d and 329 +/- 232 pg/mL, respectively (P < 0.001). By contrast, proteinuria and TNF-alpha did not change in the control group. Regression analysis showed a significant correlation between proteinuria and serum TNF-alpha both at basal (r = 0.55) and at the sixth month (r = 0.57). Furthermore, the reduction of urinary protein excretion was strongly correlated with the decrease of TNF-alpha (r = 0.72, P < 0.01). Serum Cr and C(Cr) remained stable in both groups during the study. Our findings suggest that cytokines might play a role in renal damage in diabetic nephropathy. PTF is effective in reducing proteinuria in diabetic patients with advanced renal failure. The anticytokine activity of PTF may be a further explanation for this antiproteinuric effect.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0272-6386
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
33
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
458-63
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10070909-Aged,
pubmed-meshheading:10070909-Diabetic Nephropathies,
pubmed-meshheading:10070909-Female,
pubmed-meshheading:10070909-Humans,
pubmed-meshheading:10070909-Male,
pubmed-meshheading:10070909-Middle Aged,
pubmed-meshheading:10070909-Pentoxifylline,
pubmed-meshheading:10070909-Prospective Studies,
pubmed-meshheading:10070909-Proteinuria,
pubmed-meshheading:10070909-Renal Agents,
pubmed-meshheading:10070909-Treatment Outcome,
pubmed-meshheading:10070909-Tumor Necrosis Factor-alpha
|
pubmed:year |
1999
|
pubmed:articleTitle |
Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration.
|
pubmed:affiliation |
Department of Nephrology, Hospital Ntra. Sra. de Candelaria, Santa Cruz de Tenerife, Spain. jgperez@arrakis.es
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|